Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
2(40%)
Results Posted
200%(2 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_1
2
40%
Ph phase_2
2
40%
Ph not_applicable
1
20%

Phase Distribution

2

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
2(40.0%)
N/ANon-phased studies
1(20.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

5

all time

Status Distribution
Active(3)
Completed(1)
Terminated(1)

Detailed Status

Terminated1
Not yet recruiting1
Recruiting1
Active, not recruiting1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
2
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (40.0%)
Phase 22 (40.0%)
N/A1 (20.0%)

Trials by Status

terminated120%
not_yet_recruiting120%
recruiting120%
active_not_recruiting120%
completed120%

Recent Activity

2 active trials
Showing 5 of 5
not_yet_recruitingphase_1

ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma.

NCT07348107
active_not_recruitingnot_applicable

Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic Leukemia

NCT07187505
recruitingphase_1

Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS)

NCT06670222
completedphase_2

All-trans Retinoic Acid, and Arsenic +/- Idarubicin

NCT00413166
terminatedphase_2

Trial of Arsenic Trioxide With Ascorbic Acid in the Treatment of Adult Non-Acute Promyelocytic Leukemia (APL) Acute Myelogenous Leukemia

NCT00184054

Clinical Trials (5)

Showing 5 of 5 trials
NCT07348107Phase 1

ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma.

Not Yet Recruiting
NCT07187505Not Applicable

Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic Leukemia

Active Not Recruiting
NCT06670222Phase 1

Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS)

Recruiting
NCT00413166Phase 2

All-trans Retinoic Acid, and Arsenic +/- Idarubicin

Completed
NCT00184054Phase 2

Trial of Arsenic Trioxide With Ascorbic Acid in the Treatment of Adult Non-Acute Promyelocytic Leukemia (APL) Acute Myelogenous Leukemia

Terminated

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5